BioMarin Pharmaceutical
BMRN
$53.24
-4.00%
BioMarin Pharmaceuticals Inc. is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases, specializing in enzyme replacement therapies, gene therapies, and other advanced treatments. The company is a recognized leader in the niche orphan drug market, with a portfolio of eight approved therapies for conditions like achondroplasia, phenylketonuria, and hemophilia. The current investor narrative is dominated by competitive dynamics in the achondroplasia treatment space, as evidenced by recent news highlighting rival BridgeBio's positive trial data, and the ongoing assessment of BioMarin's ability to defend its market position and drive growth from its expanding, yet early-stage, pipeline.…
BMRN
BioMarin Pharmaceutical
$53.24
Related headlines
BMRN 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on BioMarin Pharmaceutical's 12-month outlook, with a consensus price target around $69.21 and implied upside of +30.0% versus the current price.
Average Target
$69.21
4 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
4
covering this stock
Price Range
$43 - $69
Analyst target range
Analyst coverage appears limited with only 4 analysts providing estimates, suggesting this may be a less-followed name among large institutions. The consensus leans bullish, as evidenced by recent institutional ratings from firms like BofA Securities, Barclays, and Wells Fargo maintaining 'Buy' or 'Overweight' equivalents throughout February and March 2026, indicating sustained positive sentiment among covering analysts. The target price range, derived from estimated EPS, implies a wide spread of outcomes; the high EPS estimate of $8.88 assumes robust execution and commercial success, while the low estimate of $8.02 reflects more conservative growth assumptions, with the average EPS estimate of $8.45 translating to a forward P/E of approximately 6.4x based on the current price, which appears very low and may signal deep value if profitability materializes as expected.
Bulls vs Bears: BMRN Investment Factors
The evidence is currently balanced but tilts bearish in the near term due to severe earnings volatility and a looming competitive threat. The bull case is anchored in a pristine financial position and compelling valuation, while the bear case focuses on operational instability and market share risk. The single most important tension is the resolution of competitive dynamics in achondroplasia: if BioMarin successfully defends its franchise, the low valuation and strong cash flow create a powerful rebound thesis; if BridgeBio gains meaningful share, it could permanently impair BioMarin's growth narrative and justify the stock's derating.
Bullish
- Strong Balance Sheet & Cash Flow: The company has a fortress balance sheet with a debt-to-equity ratio of 0.106 and a current ratio of 5.21, indicating minimal leverage and high liquidity. It generated $725 million in trailing free cash flow, providing ample internal funding for its R&D pipeline without shareholder dilution.
- Analyst Consensus Remains Bullish: Despite recent price weakness, major institutions like BofA and Barclays maintain 'Buy' or 'Overweight' ratings. The average analyst EPS estimate of $8.45 implies a forward P/E of just 6.4x based on the current price, suggesting deep value if earnings materialize.
- Attractive Valuation on Key Metrics: The stock trades at a trailing PS ratio of 3.54, which is at the low end of its historical range (having been as high as 35.8). The forward PS ratio implied by analyst revenue estimates is approximately 2.24, pricing in significant growth at a discount.
- Recent Quarterly Revenue Growth Rebound: Q4 2025 revenue grew 17.03% year-over-year to $874.6 million, a strong recovery from the Q3 dip to $776.1 million. This demonstrates the underlying commercial strength and potential of its rare disease portfolio despite quarterly lumpiness.
Bearish
- Severe Profitability & Margin Volatility: The company swung from a $240.5 million net income in Q2 2025 to a -$46.6 million loss in Q4 2025. Gross margin collapsed from 81.82% in Q2 to 66.26% in Q4, indicating severe product mix issues or cost pressures that undermine earnings predictability.
- Intensifying Competitive Threat in Key Market: Recent news highlights rival BridgeBio's positive Phase 3 data for an achondroplasia treatment, with an FDA filing planned for 2026. This directly threatens BioMarin's Voxzogo franchise, a key growth driver, and could lead to significant market share erosion.
- Sustained Technical Downtrend & Weakness: The stock is down 12.85% over the past year and 20.34% over the past month, severely underperforming the S&P 500. It trades at just 20.8% of its 52-week range, near its $50.76 low, reflecting persistent selling pressure and bearish sentiment.
- Limited Analyst Coverage & High Short Interest: Only 4 analysts provide estimates, suggesting lower institutional interest and potentially less liquidity support. A short ratio of 4.51 indicates a significant portion of the float is sold short, betting on further price declines.
BMRN Technical Analysis
The stock is in a sustained downtrend, with a 1-year price change of -12.85%, significantly underperforming the broader market. The current price of $53.98 sits at just 20.8% of its 52-week range, calculated from the 52-week low of $50.76 and high of $66.28, positioning it near the lower bounds of its annual trading band, which suggests a potential value opportunity but also reflects significant bearish sentiment and technical weakness. Recent momentum shows continued pressure, with the stock down 20.34% over the past month and 3.97% over the past three months, indicating that the negative momentum is accelerating in the short term and diverging sharply from the S&P 500's positive returns over the same periods. Key technical support is clearly defined at the 52-week low of $50.76, while resistance lies at the 52-week high of $66.28; a breakdown below $50.76 would signal a new leg down, while a recovery above the recent highs near $64 would be needed to suggest a trend reversal. The stock's beta of 0.291 indicates it is approximately 71% less volatile than the market, which is unusually low for a biotech and suggests it has been trading more on idiosyncratic, company-specific news rather than broader market moves.
Beta
0.23
0.23x market volatility
Max Drawdown
-27.2%
Largest decline past year
52-Week Range
$51-$66
Price range past year
Annual Return
-14.2%
Cumulative gain past year
| Period | BMRN Return | S&P 500 |
|---|---|---|
| 1m | -4.1% | +10.4% |
| 3m | -7.6% | +5.5% |
| 6m | +2.7% | +8.0% |
| 1y | -14.2% | +28.4% |
| ytd | -10.4% | +6.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BMRN Fundamental Analysis
Revenue growth has been volatile but showed a strong 17.03% year-over-year increase in the most recent quarter (Q4 2025), reaching $874.6 million; however, examining the quarterly income statements reveals inconsistency, with revenue dipping to $776.1 million in Q3 2025 before the Q4 rebound, indicating lumpy sales rather than a smooth upward trajectory. Profitability is highly erratic, as evidenced by a net income of -$46.6 million in Q4 2025 following a net income of $240.5 million in Q2 2025, while the gross margin of 66.26% in Q4 was a significant compression from the 81.82% reported in Q2, pointing to potential product mix issues or cost pressures. The balance sheet and cash flow position remain a strength, with a robust current ratio of 5.21, a very low debt-to-equity ratio of 0.106, and strong trailing twelve-month free cash flow of $725.0 million, indicating ample liquidity, minimal financial leverage, and the internal capacity to fund its R&D pipeline without reliance on dilutive external financing.
Quarterly Revenue
$874565000.0B
2025-12
Revenue YoY Growth
+0.17%
YoY Comparison
Gross Margin
+0.66%
Latest Quarter
Free Cash Flow
$724956000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BMRN Overvalued?
Given the inconsistent profitability with a recent quarterly net loss, the Price-to-Sales (PS) ratio is the most appropriate primary valuation metric. The trailing PS ratio is 3.54, while the forward-looking valuation, implied by the market cap and analyst revenue estimates, suggests a forward PS of approximately 2.24 ($11.4B market cap / $5.09B estimated revenue), indicating the market anticipates significant revenue growth and potential margin improvement. Compared to industry averages, data is not available in the provided dataset for a direct sector PS comparison, limiting the peer analysis. Historically, the stock's current PS ratio of 3.54 is at the low end of its own historical range observed in the provided data, which has seen PS ratios as high as 35.8 in late 2021; this steep de-rating suggests the market has significantly tempered its growth and profitability expectations for BioMarin, potentially pricing in a more mature, slower-growth profile or competitive threats.
PE
32.7x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -19329x~295x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
18.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks center on extreme earnings volatility, as evidenced by the swing from a $240.5M profit to a -$46.6M loss within six months, and gross margin compression from 82% to 66%. This lumpiness makes forecasting difficult and suggests underlying commercial or cost control issues. Revenue concentration risk is heightened by the specific competitive threat to Voxzogo. The company's low beta of 0.29, while reducing market risk, confirms that its stock moves are driven by these volatile, company-specific operational results.
Market & Competitive Risks are acute, with BridgeBio's promising achondroplasia data posing a direct challenge to a core growth franchise. Valuation compression has already occurred, with the PS ratio falling from a historical high of 35.8 to 3.54, but further de-rating is possible if growth expectations are downgraded. The stock's low trading volume and limited analyst coverage (only 4 analysts) increase liquidity risk and the potential for exaggerated moves on news. Sector rotation away from biotech or regulatory setbacks for pipeline candidates are additional external threats.
Worst-Case Scenario involves BridgeBio's therapy gaining rapid FDA approval and superior market uptake, severely curtailing Voxzogo's growth and leading to successive quarters of earnings misses and guidance cuts. This could trigger analyst downgrades and a loss of investor confidence, driving the stock to re-test and break its 52-week low of $50.76. Given the current price of $53.98, this implies a realistic immediate downside of approximately -6%. A more severe scenario, factoring in a further valuation derating, could see the stock fall toward the $45-$48 range, representing a potential loss of -10% to -17% from current levels.